Durinck S,Ho C,Wang NJ,Liao W,Jakkula LR,Collisson EA,Pons J,Chan SW,Lam ET,Chu C,Park K,Hong SW,Hur JS,Huh N,Neuhaus IM,Yu SS,Grekin RT,Mauro TM,Cleaver JE,Kwok PY,Leboit PE,Getz G,Cibulskis K,Aster JC,Huang H,Purdom E,Li J,Bolund L,Arron ST,Gray JW,Spellman PT and Cho RJ
Life Sciences Division, Lawrence Berkeley National Laboratories, CA.
Timely intervention for cancer requires knowledge of its earliest genetic aberrations. Sequencing of tumors and their metastases reveals numerous abnormalities occurring late in progression. A means to temporally order aberrations in a single cancer, rather than inferring them from serially acquired samples, would define changes preceding even clinically evident disease. We integrate DNA sequence and copy number information to reconstruct the order of abnormalities as individual tumors evolve for two separate cancer types. We detect vast, unreported expansion of simple mutation sharply demarcated by recombinative loss of the second copy of TP53 in cutaneous squamous cell carcinomas (cSCCs) and serous ovarian adenocarcinomas, in the former surpassing 50 mutations per megabase. In cSCCs, we also report diverse secondary mutations in known and novel oncogenic pathways, illustrating how such expanded mutagenesis directly promotes malignant progression. These results reframe paradigms in which TP53 mutation is required later, to bypass senescence induced by driver oncogenes.